CalciMedica Unveils 2025 Financial Results and Key Clinical Progress

CalciMedica Inc., a clinical-stage biopharmaceutical company based in La Jolla, California, has released its financial results for the year ending December 31, 2025, alongside important updates on its clinical programs. The company focuses on developing innovative therapies targeting calcium release-activated calcium (CRAC) channels for managing acute and chronic inflammatory and immunologic diseases.

In a significant finding, CalciMedica has concluded that a comprehensive review of safety data from the Phase 2 KOURAGE trial, which investigates Auxora in patients with acute kidney injury (AKI), did not reveal any sign of drug-related toxicity. This information is crucial as the company prepares to engage with the U.S. Food and Drug Administration (FDA) regarding future clinical studies in AKI.

Clinical Updates and Program Highlights

The KOURAGE trial, initially assessing Auxora’s efficacy in patients with Stage 2 or Stage 3 AKI, was temporarily halted in January 2026 due to safety concerns highlighted by the Independent Data Monitoring Committee (IDMC). Although the IDMC found no evidence of drug-related toxicity, the committee recommended a reassessment of the study’s design due to a noted mortality imbalance among participants. CalciMedica plans to discuss the trial’s findings and potential next steps with the FDA in the second quarter of 2026.

CalciMedica is also advancing Auxora towards a pivotal program in acute pancreatitis (AP). The company has reported constructive dialogue with the FDA, aiming to finalize the program design in the first half of 2026. Notably, AP results in approximately 300,000 hospitalizations annually in the United States alone. A recent publication in eClinicalMedicine detailed the Phase 2b CARPO trial, showing that Auxora significantly improved time to solid food tolerance and reduced rates of organ failure among patients with systemic inflammatory response syndrome.

In addition, CalciMedica’s second CRAC channel inhibitor, CM5480, is making strides towards treating pulmonary arterial hypertension (PAH). A manuscript published in JCI Insight highlights preclinical data that supports CM5480’s potential as a first-in-class therapy. The research indicates that CM5480 can restore heart function and improve patient outcomes in PAH models.

Financial Performance Overview

For the year ended December 31, 2025, CalciMedica reported a cash position of $13.0 million, which is expected to sustain its operations into the fourth quarter of 2026. Research and development expenses for the year totaled $15.2 million, an increase from $14.5 million in 2024, largely driven by heightened clinical trial activities.

General and administrative expenses decreased to $7.9 million in 2025 from $9.7 million the previous year, reflecting a reduction in consultancy costs despite an increase in personnel expenses linked to stock-based compensation. Overall, CalciMedica reported a net loss of $29.6 million, or $1.97 per share, a significant increase from a net loss of $13.7 million in 2024.

CalciMedica’s leadership, including Chief Executive Officer Dr. Rachel Leheny, remains optimistic about the company’s future prospects, particularly in light of the ongoing advancements in its clinical programs and the encouraging data emerging from recent trials. The company is committed to addressing unmet medical needs through its innovative therapies, which may provide essential benefits in treating serious conditions like AKI, AP, and PAH.

For more detailed information about CalciMedica and its operations, visit the company’s website at www.calcimedica.com.